Harnessing the AI/ML in Drug and Biological Products Discovery and Development: The Regulatory Perspective
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Artificial Intelligence (AI) has the disruptive potential to transform patients’ lives via innovations in pharmaceutical sciences, drug development, clinical trials, and manufacturing. However, it presents significant challenges, ethical concerns, and risks across sectors and societies. AI’s rapid advancement has revealed regulatory gaps as existing public policies struggle to keep pace with the challenges posed by these emerging technologies. The term AI itself has become commonplace to argue that greater “human oversight” for “machine intelligence” is needed to harness the power of this revolutionary technology for both potential and risk management, and hence to call for more practical regulatory guidelines, harmonized frameworks, and effective policies to ensure safety, scalability, data privacy, and governance, transparency, and equitable treatment. In this review paper, we employ a holistic multidisciplinary lens to survey the current regulatory landscape with a synopsis of the FDA workshop perspectives on the use of AI in drug and biological product development. We discuss the promises of responsible data-driven AI, challenges and related practices adopted to overcome limitations, and our practical reflections on regulatory oversight. Finally, the paper outlines a path forward and future opportunities for lawful ethical AI. This review highlights the importance of risk-based regulatory oversight, including diverging regulatory views in the field, in reaching a consensus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
I.—COMPUTING MACHINERY AND INTELLIGENCE
TURING, A. M. (1950) · Mind · doi:10.1093/mind/lix.236.433 · Cited by 10,290 · cited 2×
“Some, like Turing, argue that if an AI behaves indistinguishably from a human, its intelligence should be considered natural [8,12].”
The global landscape of AI ethics guidelines
Jobin, A., Ienca, M., & Vayena, E. (2019) · Nature Machine Intelligence · doi:10.1038/s42256-019-0088-2 · Cited by 6,220
Duan, Y., Edwards, J. S., & Dwivedi, Y. K. (2019) · International Journal of Information Management · doi:10.1016/j.ijinfomgt.2019.01.021 · Cited by 2,628 · cited 1×
“They widened systematic medical image analysis by AI for computer-guided diagnosis and physician labor reduction [2].”
Vasey, B., Nagendran, M., Campbell, B., Clifton, D. A., Collins, G. S., Denaxas, S., Denniston, A. K., Faes, L., Geerts, B., Ibrahim, M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01772-9 · Cited by 1,039
Addressing bias in big data and AI for health care: A call for open science
Norori, N., Hu, Q., Aellen, F. M., Faraci, F. D., & Tzovara, A. (2021) · Patterns · doi:10.1016/j.patter.2021.100347 · Cited by 903
Artificial Intelligence Transforms the Future of Health Care
Noorbakhsh-Sabet, N., Zand, R., Zhang, Y., & Abedi, V. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.01.017 · Cited by 626
Fink, O., Wang, Q., Svensén, M., Dersin, P., Lee, W.-J., & Ducoffe, M. (2020) · Engineering Applications of Artificial Intelligence · doi:10.1016/j.engappai.2020.103678 · Cited by 549
Towards hybrid human‐AI learning technologies
Molenaar, I. (2022) · European Journal of Education · doi:10.1111/ejed.12527 · Cited by 348
Matching patients to clinical trials with large language models
Jin, Q., Wang, Z., Floudas, C. S., Chen, F., Gong, C., Bracken-Clarke, D., Xue, E., Yang, Y., Sun, J., & Lu, Z. (2024) · Nature Communications · doi:10.1038/s41467-024-53081-z · Cited by 287 · cited 3×
“In clinical research, tools like Criteria2Query and TrialGPT exemplify how AI-driven systems enhance trial designs by automating patient matching, reducing reliance on control groups, and addressing biases to promote inclusivity [49,50].”
Matching Patients to Clinical Trials with Large Language Models
Jin, Q., Wang, Z., Floudas, C. S., Chen, F., Gong, C., Bracken-Clarke, D., Xue, E., Yang, Y., Sun, J., & Lu, Z. (2023) · arXiv · doi:10.48550/arxiv.2307.15051 · Cited by 287
Molenaar, I. (2022) · Computers and Education: Artificial Intelligence · doi:10.1016/j.caeai.2022.100070 · Cited by 217 · cited 1×
“Several cognitive scientists, AI experts, and philosophers suggest that AI research can provide insights into the workings of the human mind [9–11].”
Larger and more instructable language models become less reliable
Zhou, L., Schellaert, W., Martínez-Plumed, F., Moros-Daval, Y., Ferri, C., & Hernández-Orallo, J. (2024) · Nature · doi:10.1038/s41586-024-07930-y · Cited by 203
AI Chatbots and Challenges of HIPAA Compliance for AI Developers and Vendors
Rezaeikhonakdar, D. (2023) · Journal of Law, Medicine & Ethics · doi:10.1017/jme.2024.15 · Cited by 67 · cited 2×
“Compliance with regulations such as the General Data Protection Regulation (GDPR) and the Health Insurance Portability and Accountability Act (HIPAA) is essential for protecting patient privacy [90,91].”
Cited by
Regulatory Perspectives for AI/ML Implementation in Pharmaceutical GMP Environments
Niazi, S. K. (2025) · Pharmaceuticals · doi:10.3390/ph18060901 · Cited by 90
Self-citationThe Importance of AI Data Governance in Large Language Models
(2025) · doi:10.3390/bdcc9060147 · Cited by 58
Abbas, S. R., Abbas, Z., Zahir, A., & Lee, S. W. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf329 · Cited by 30
Metadata
- Authors
- Mirakhori, F., & Niazi, S. K.
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2025-01-03
- Volume
- 18
- Issue
- 1
- Pages
- 47
- ISSN
- 1424-8247 (ISSN-L)
- OpenAlex
- W4406033696
- Cited by
- 143
- References
- 13
- FWCI
- 29.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.